Patrick Baeuerle - 17 Feb 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Reporting relationship: Chief Scientific Officer
Issuer ticker: CGEM
Reported as of: 17 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Feb 2023, 17:53:33 UTC
Prior SEC filing: 15 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer, Attorney-in-Fact

Key filing fact

Patrick Baeuerle filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 21 Feb 2023.

Key facts

This page summarizes Patrick Baeuerle's Form 4 filing for Cullinan Oncology, Inc. (CGEM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Feb 2023, 17:53.

Change

Previous filing in this sequence was filed on 15 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGEM transaction

Common Stock

Award

Transaction value: $0
Shares: +38,500
Change %: +103%
Price: $0.000000
Shares after: 76,000
Date: 17 Feb 2023
Ownership: Direct
Footnotes: F1

CGEM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 341,434
Date: 17 Feb 2023
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +77,000
Change %
Price: $0.000000
Shares after: 77,000
Date: 17 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 77,000
Exercise price: $11.34
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares underlying the restricted stock unit vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

Footnote F2

Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Footnote F3

The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

SEC remarks

Exhibit 24.1 - Power of Attorney